Table 2. Patient outcomes and immune response to vaccines.

Subjects are stratified by clinical status at the time of the report. Upper table: no evidence of disease (NED; n=9). Lower table: recurrence / progression (n=5). Site of recurrent / progressive disease and status of the subject at the time of the repost is noted. Immunologic response measured by IFN-γ ELISPOT is indicated by positive ( + ; n=9) or negative ( − ; n=5). Stage grouping of TNM subsets is shown for each subject. Also shown is months from completion of definitive therapy and months from second vaccine at the time of the report.

Patient number	Stage	Months from conventional treatment	Months from 2nd vaccine	Recurrence from 2nd vaccine (months)	Status at time of report	Immunologic Response
DC17	IB	51	23	-	NED	+
DC18	IIIB	51	24	-	NED	+
DC20	IA	33	22	-	NED	−
DC22	IIIA	27	18	-	NED	−
DC24	IIIA	23	18	-	NED	+
DC26	IA	32	14	-	NED	+
DC27	IA	38	13	-	NED	+
DC28	IB	28	13	-	NED	+
DC29	IIB	17	12	-	NED	+
DC19	IIIB	Expired 12	Expired 6	3	Progression Loco-regional Expired	−
DC21	IIIB/IV	Expired 6	Expired 2	2	Progression Loco-regional Expired	+
DC23	IB	25	17	3	Metastasis Skeletal Stable	+
DC25	IIIA	Expired 7	Expired 2	<1	Progression Loco-regional Expired	−
DC30	IIIB	21	10	1	Metastasis Brain Stable	−